



OCTOBER 5th & 6th 2020
PARIS

Organized by



Health



EIT Health is supported by the EIT,
a body of the European Union

EDITO

Maryvonne Hiance
President of HTID®



Dear attendees,

Welcome to the second edition of the HealthTech Innovation Days.

Europe is a land of innovation in the field of health sciences. Many start-ups and SMEs are seeking funding to make their innovations available to patients and meet tomorrow's medical challenges. Healthcare access and treatment for every individual is a societal priority, now more than ever.

The event, which is led by the endowment fund HealthTech For Care, founded by France Biotech and co-organized with EIT Health, aims to foster collaborations within the European healthcare and life sciences ecosystems and accelerate the commercialization of new drugs and therapeutic solutions. For this edition, which is organized both as a virtual and in-person event, we have more than 100 European healthtech companies, 300 international investors from Europe, North America, Australia, Asia and the Middle East and more than 15 leading pharmaceutical groups actively acting to build a stronger and sovereign healthcare ecosystem in France and Europe.

The event is a springboard for driving relationships among key players from across the healthcare community.

Jean-Marc Bourez
Managing Director of EIT Health France
and Head of the VCoE



Dear HTID attendees,

After a challenging start to the year at both international and national levels due to the Covid-19 health crisis, we are thrilled to finally hold the second edition of HTID® on October 5&6.

Whilst the Covid-19 crisis put a stop to all the networking events that are key to insuring the good functioning of the health innovation ecosystem, we are happy that this edition of HTID can be held in a mixed online and face-to-face format adapted to the Covid-19 sanitary precautions.

More than ever, the past few months have shown us that it is essential to strengthen the support available for health innovation in Europe. It is with this aim that 2020 HTID® gathers key actors from the European innovation and investment ecosystems, around a rich and varied programme.

As co-organisers of the event, we are confident that by bringing such actors together, we will concretely further the successful development of European and international healthcare innovation.

Maryvonne Hiance & Jean-Marc Bourez wish you an enjoyable and successful experience at HTID 2020.

PRESENTATION



The HealthTech Innovation Days aim to drive and foster collaborations within the European healthcare ecosystem. This second edition of HTID®, this year held by HealthTech For Care, an endowment fund launched by France Biotech and co-organized with EIT Health, will accelerate patient access to healthcare solutions and contribute to building a stronger health ecosystem. This symposium features private meetings between innovative European healthtech companies, pharmaceutical companies, life sciences-specialized investors, healthcare experts, KOLs and institutional representatives.

In addition to the ongoing private meetings, attendees can expect roundtables focused on critical economic and political issues that impact health technology developments. HTID® is attended for European healthcare companies willing to accelerate their innovations: Biotech companies whose drug candidates are currently undergoing late Phase I studies, Medtech companies with CE mark or FDA approval medical devices and Digital-health companies, having carried out a first round of financing or a secure partnership with a pharmaceutical company.



The HealthTech For Care endowment fund, launched by France Biotech, is designed to support and promote access to care for all and, more specifically, to support new medical technologies and drugs.

The missions of the endowment fund are structured around three main areas: Supporting the development of the entire health ecosystem, accelerating the development of innovative therapies and treatments, and promoting better access to healthcare for patients in the French healthcare system and more widely throughout Europe.

HealthTech For Care is administrated by the President Maryvonne Hiance and a board : Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.




Founded in 1997, France Biotech is an independent association that brings together the country's leading innovative health companies and their expert partners. As a leader in health innovation and a privileged intermediary with public authorities in France and Europe, France Biotech's mission is to support

the development of this industry in France by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry. France Biotech also aims to turn French innovative health technology companies into world leaders capable of designing and developing new innovations quickly and making them available and accessible to patients.

France Biotech has founded and is developing the "HealthTech For Care" fund to strengthen the ability to federate, structure and encourage cooperation between the various stakeholders in the health tech sector in France and Europe. France Biotech is chaired by Franck Mouthon, CEO of Theranexus.

PRESENTATION



EIT Health is supported by the EIT,
a body of the European Union

EIT Health is a network of best-in-class health innovators including approximately 150 partners and is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. We collaborate across borders to deliver new solutions that can enable European citizens to live longer, healthier lives.

As Europeans tackle the challenge of increasing chronic diseases and multi-morbidity, and seek to promote the opportunities that technology offers to move beyond conventional approaches to treatment, prevention and healthy lifestyles, we need thought leaders, innovators and efficient ways to bring innovative healthcare solutions to market.

EIT Health addresses these needs. We connect all relevant healthcare players across European borders – making sure to include all sides of the “knowledge triangle”, so that innovation can happen at the intersection of research, education and business for the benefit of citizens.

Venture Centre of Excellence Launch

The Venture Centre of Excellence (VCoE) is a public/private co-investment programme co-developed by EIT Health and the European Investment Fund (EIF) and backed by an anchor investment of up to €150M from the European Commission.

This contribution, in addition to EIF's primary investments, will provide a basis to leverage funds brought in by members, bringing the total economic impact of the VCoE to €2bn over 15 years.

This programme aims to facilitate access to finance for health start-ups completing Series A and beyond in syndication, up to pre-IPO. To do so, the VCoE will bring together as a community 15 to 20 VCs, selected amongst EIF's European network, and maximum 30 of EIT Health's Corporates/academics/payers/TTO partners. A trusting relationship will be established amongst the community's members, allowing the sharing of investment opportunities, including through the organisation of exclusive bi-annual events.

In addition, the VCoE will use an Artificial Intelligence-based platform developed by Skopai to build strategic partnerships and share co-investment opportunities adapted to investors' criteria.

The platform will also feature and showcase start-ups whose excellence will be certified by a vetting process established by EIT Health.

EIT Health and the EIF are launching the Venture Centre of Excellence at HTID and organising roundtables on Life Science investment opportunities in Europe during the event.

OUR PARTNERS

Platinum



Super Gold



Gold



Silver



Bronze




NOTES

[illegible]

This image shows a blank sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

THE PENINSULA PLAN



Our supports

france
biotech
biotech | medtech | e-santé | IA
LES ENTREPRENEURS DE LA HEALTHTECH

inova

LallianSe

SternIR

ATLANPOLE
biotherapies

france
BIOVALLEY
l'innovation santé

Eurobiomed

CLUBSTER
NHL
Nutrition Health Longevity

LYONBIOPOLE
Auvergne - Rhône - Alpes

ME di CEN
PARIS REGION

AFMTELETHON
INNOVER POUR GUERIR

5
ambitions
françaises

ThermoFisher
SCIENTIFIC

MC SERVICES

RP
RooneyPartners

S&I
STRATEGIES & IMAGE

ShapeNLink

Nathalie Donne
Senior Project Manager
nathalie.donne@shapenlink.com
+33(0)6 67 67 44 97

Anne Rein - Media contact
StrategiesImage (S&I) - France
anne.rein@strategiesimage.com
+33(0)6 03 35 92 05

Estelle Metzger
Project Manager
HealthTech For Care
estelle.metzger@htid-paris.com

Inova Software
Olivier Duchamp
support@inova-event.com

Solène Goupy
Communication Manager
HealthTech For Care
solene.goupy@htid-paris.com

SternIR contact
Rhannon Davies
Office Direct: +1-212-698-8700